Get alerts:The company also reported $15 million in license revenue from a sales-based milestone under its agreement with Secura Bio. VS-7375 Development Programs AdvanceVerastem completed target enrollment in dose-expansion cohorts of the TARGET-D 101 study of VS-7375 in pancreatic cancer, colorectal cancer and non-small cell lung cancer. For colorectal cancer, Paterson said Verastem does not intend to develop VS-7375 as a monotherapy and expects to use it with an EGFR inhibitor. Calkins said Verastem expects quarterly SG&A spending to remain roughly stable through 2026 as it supports the CO-PACK launch while maintaining expense discipline. About Verastem (NASDAQ:VSTM)Verastem Oncology, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapies that target cancer stemness and resistance pathways.